세계의 HIV 진단 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global HIV Diagnostics Market was valued at USD 2.5 billion in 2024 and is estimated to grow at a CAGR of 5.2% to reach USD 4 billion by 2034. This upward trend is supported by rising HIV incidence in lower- and middle-income regions, combined with the demand for more reliable and accessible diagnostic methods. As awareness surrounding HIV testing grows through global campaigns, both public and private healthcare systems are increasingly adopting advanced testing solutions. Point-of-care diagnostics are gaining momentum due to their speed, convenience, and suitability in regions with limited infrastructure.

Diagnostic technologies used to identify HIV infections play a central role in early intervention, patient monitoring, and determining suitable treatment paths. Various global health efforts and funding initiatives continue to create demand for accessible HIV testing solutions. As access to healthcare and health literacy improve, the adoption of HIV testing kits, especially in underserved communities, continues to rise. Technological innovation and faster, cost-efficient testing solutions are further supporting widespread adoption across both public health initiatives and clinical settings. The combination of policy support, increasing public awareness, and rapid diagnostic advancements continues to reshape the HIV diagnostics landscape globally.

The antibody tests segment led the market in 2024 and held the largest share due to their cost-effectiveness, simplicity, and ability to deliver quick results. Their growing use in self-testing kits has also contributed to widespread adoption, particularly in low-resource environments. These tests are ideal for mass screening as they are both accessible and easy to administer without requiring complex medical settings. Their relevance continues to grow as more individuals opt for privacy-driven self-testing methods, especially in regions where healthcare stigma or limited access to clinics is a concern.

The diagnostic laboratories segment held 45.9% share in 2024. These facilities remain the preferred choice for HIV testing because they are equipped to manage a large volume of tests efficiently. With growing HIV prevalence, the need for accurate and high-throughput testing is expanding. Laboratories utilize sophisticated instruments and automated systems to deliver reliable results, making them essential for supporting public health programs and large-scale testing campaigns.

Middle East and Africa HIV Diagnostics Market held 30.1% share in 2024. Rising infection rates in this region continue to fuel demand for more effective and accessible diagnostic tools. As more awareness and resources are directed toward managing the spread of HIV, the need for scalable and accurate testing solutions continues to drive the market forward.

Leading companies in the HIV Diagnostics Market include Bioneer, Hologic, Genlantis Diagnostics, Qiagen, ChemBio Diagnostics, OraSure Technologies, Becton, Dickinson and Company (BD), F. Hoffmann-La Roche, Abbott Laboratories, Biomerieux, and Cepheid. Major players in the HIV diagnostics sector are reinforcing their market presence by expanding testing portfolios, enhancing point-of-care platforms, and investing in R&D. Many are launching next-generation diagnostic kits that prioritize speed, portability, and accuracy, tailored for decentralized healthcare settings.

Collaborations with healthcare agencies, NGOs, and governments help companies secure large-scale supply contracts, while regional expansion through local partnerships strengthens distribution. To remain competitive, several firms are integrating digital tools with testing kits, enabling real-time data tracking and remote monitoring. Others focus on regulatory approvals and certifications to accelerate market entry in underserved regions with rising HIV incidence.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Test type
  • 2.2.3 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising AIDS/HIV prevalence in low and middle-income countries
    • 3.2.1.2 Increasing government initiatives for HIV awareness
    • 3.2.1.3 Point-of-care (POC) HIV diagnostics development
    • 3.2.1.4 Favorable regulatory landscape in the U.S.
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Low degree of penetration in underdeveloped market
    • 3.2.2.2 Social stigma and discrimination
  • 3.2.3 Market opportunities
    • 3.2.3.1 Ongoing technology advancement
    • 3.2.3.2 Integration with digital health platforms
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technological advancements
• 3.6 Pricing analysis, 2024
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic outlook matrix
• 4.7 Strategic dashboard
• 4.8 Key developments
  • 4.8.1 Mergers and acquisitions
  • 4.8.2 Partnerships and collaborations
  • 4.8.3 New product launches
  • 4.8.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Antibody test
• 5.3 Viral load test
• 5.4 CD4 test

Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diagnostic laboratories
• 6.3 Hospitals and clinics
• 6.4 Home settings
• 6.5 Other end use

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 India
  • 7.4.3 Japan
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 South Africa
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 Becton, Dickinson and Company (BD)
• 8.3 Biomerieux
• 8.4 Bioneer
• 8.5 Cepheid
• 8.6 ChemBio Diagnostics
• 8.7 F. Hoffmann-La Roche
• 8.8 Genlantis Diagnostics
• 8.9 Hologic
• 8.10 OraSure Technologies
• 8.11 Qiagen